An interventional study of Structured Cardiovascular Risk Management in Cardiovascular Risk Factors, Hypertension and Dyslipidemia, sponsored by Universidad Católica San Antonio de Murcia. Recruiting at 1 site in Chile. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Universidad Católica San Antonio de Murcia · Not applicable, Interventional, and Prevention
This study aims to evaluate cardiovascular risk factors, clinical characteristics, and outcomes in adult patients attending an outpatient cardiology clinic. The research focuses on identifying predictors of adverse cardiovascular events, optimizing risk stratification, and improving preventive strategies in routine clinical practice. Data will be collected from patients receiving standard cardiology care without altering their treatment. The results are expected to contribute to better understanding of cardiovascular risk profiles and to support improvements in clinical decision-making and patient management.
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's planned enrollment of 220 is above the median of 100 across 4,575 interventional studies indexed under Hypertension.
Browse Hypertension studies →Universidad Católica San Antonio de Murcia is the lead sponsor of 138 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive structured clinical follow-up with periodic assessment of cardiovascular risk factors and adjustment of pharmacological and lifestyle management according to current clinical guidelines over a 120-day follow-up period.
Other: Structured Cardiovascular Risk Management
Protocol-based clinical management including periodic evaluation and adjustment of antihypertensive, lipid-lowering, antidiabetic, and lifestyle interventions according to routine clinical practice guidelines.
Change in systolic blood pressure
Change in systolic blood pressure (mmHg) measured under standardized conditions to evaluate the effect of structured clinical and pharmacological cardiovascular risk management.
Time frame: Baseline to 90 days
Change in diastolic blood pressure
Evaluation of changes in diastolic blood pressure following structured clinical and pharmacological management.
Time frame: Baseline to 90 days
Change in LDL cholesterol
Evaluation of changes in LDL cholesterol measured during routine laboratory assessment after structured cardiovascular risk management.
Time frame: Baseline to 90 days
Change in HbA1c
Evaluation of changes in glycated hemoglobin (HbA1c) following structured cardiovascular risk management.
Time frame: Baseline to 90 days
Change in body weight
Evaluation of changes in body weight following lifestyle counseling and structured cardiovascular risk management.
Time frame: Baseline to 90 days
Change in renal function (eGFR)
Evaluation of changes in renal function assessed by estimated glomerular filtration rate following structured cardiovascular risk management.
Time frame: Baseline to 90 days
Change in HDL cholesterol
Evaluation of changes in HDL cholesterol measured during routine laboratory assessment after structured cardiovascular risk management.
Time frame: Baseline to 90 days
Change in triglycerides
Evaluation of changes in triglyceride levels measured during routine laboratory assessment after structured cardiovascular risk management.
Time frame: Baseline to 90 days
Change in total cholesterol
Evaluation of changes in total cholesterol measured during routine laboratory assessment after structured cardiovascular risk management.
Time frame: Baseline to 90 days
Change in fasting plasma glucose
Evaluation of changes in fasting plasma glucose following structured cardiovascular risk management.
Time frame: Baseline to 90 days
Change in body mass index
Evaluation of changes in body mass index following lifestyle counseling and structured cardiovascular risk management.
Time frame: Baseline to 90 days
Change in microalbuminuria
Evaluation of changes in urinary albumin excretion to assess microalbuminuria during follow-up after structured cardiovascular risk management.
Time frame: Baseline to 90 days
Plan to share: No — Individual participant data will not be shared due to privacy regulations and institutional data protection policies. De-identified aggregated results will be available through scientific publication.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Católica San Antonio de Murcia →